Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature

The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in association with endocrine therapy (ET). However, even if t...

Full description

Bibliographic Details
Main Authors: Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Diagnostics
Subjects:
CDK4/6 inhibitors
advanced/metastatic breast cancer
biomarkers of response
progression on CDK4/6 inhibitors
resistance mechanisms
endocrine therapy
Online Access:https://www.mdpi.com/2075-4418/13/5/987

Internet

https://www.mdpi.com/2075-4418/13/5/987

Similar Items